Cook Medical Inc.(Bloomington, IN) has reported results on the first trial to investigate whether paclitaxel-eluting stents can be used to successfully treat peripheral arterial disease (PAD). The company’s Zilver PTX Paclitaxel-Eluting Stent trial results demonstrated no stent fractures, and the major adverse event (MAE) rate was equivalent to conventional balloon angioplasty treatment at its 6th-month follow-up point.
Michael Dake, MD, national principal investigator for Cook’s Zilver PTX Drug-Eluting Stent Trial, presented 9-month data on the first 60 patients in the randomized trial examining the safety of using...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?